Mesa Laboratories, Inc. (NASDAQ:MLAB) Director H Stuart Campbell sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $143.09, for a total transaction of $143,090.00. Following the sale, the director now owns 47,976 shares of the company’s stock, valued at $6,864,885.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
H Stuart Campbell also recently made the following trade(s):
- On Thursday, August 3rd, H Stuart Campbell sold 2,000 shares of Mesa Laboratories stock. The stock was sold at an average price of $143.37, for a total transaction of $286,740.00.
Mesa Laboratories, Inc. (NASDAQ:MLAB) traded down 0.85% during trading on Friday, reaching $141.52. 26,406 shares of the company were exchanged. The firm has a 50-day moving average of $144.28 and a 200-day moving average of $135.20. The firm has a market cap of $531.83 million, a price-to-earnings ratio of 50.87 and a beta of 0.46. Mesa Laboratories, Inc. has a 52-week low of $102.14 and a 52-week high of $169.80.
Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.56 by $0.17. The business had revenue of $22.67 million for the quarter, compared to the consensus estimate of $22.90 million. Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. On average, equities analysts forecast that Mesa Laboratories, Inc. will post $2.72 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 31st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend is Tuesday, August 29th. Mesa Laboratories’s dividend payout ratio is currently 22.94%.
ILLEGAL ACTIVITY WARNING: “Mesa Laboratories, Inc. (NASDAQ:MLAB) Director H Stuart Campbell Sells 1,000 Shares” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/08/05/mesa-laboratories-inc-nasdaqmlab-director-h-stuart-campbell-sells-1000-shares.html.
A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Mesa Laboratories from a “buy” rating to a “strong sell” rating in a report on Thursday. TheStreet cut shares of Mesa Laboratories from a “b” rating to a “c+” rating in a report on Monday, July 31st. Finally, BidaskClub cut shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a report on Monday, July 31st.
A number of hedge funds and other institutional investors have recently modified their holdings of MLAB. Strs Ohio boosted its position in shares of Mesa Laboratories by 5.6% in the second quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock worth $272,000 after buying an additional 100 shares in the last quarter. Eqis Capital Management Inc. boosted its position in shares of Mesa Laboratories by 5.6% in the second quarter. Eqis Capital Management Inc. now owns 5,188 shares of the medical instruments supplier’s stock worth $744,000 after buying an additional 273 shares in the last quarter. Spark Investment Management LLC purchased a new position in shares of Mesa Laboratories during the second quarter worth about $300,000. Bessemer Group Inc. boosted its position in shares of Mesa Laboratories by 716.7% in the second quarter. Bessemer Group Inc. now owns 4,900 shares of the medical instruments supplier’s stock worth $702,000 after buying an additional 4,300 shares in the last quarter. Finally, Thomson Horstmann & Bryant Inc. boosted its position in shares of Mesa Laboratories by 75.4% in the second quarter. Thomson Horstmann & Bryant Inc. now owns 72,362 shares of the medical instruments supplier’s stock worth $10,370,000 after buying an additional 31,107 shares in the last quarter. Hedge funds and other institutional investors own 66.90% of the company’s stock.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
